Pure Global AI
NCT05917028Not yet recruiting

Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis

A Single Arm, Single Center, Open Label , Pilot Clinical Study to Evaluate the Efficacy and Safety of Transcatheter Arterial Micro Embolization (TAME) Using Nexsphere F in Patients With Knee Degenerative Osteoarthritis
Next Biomedical Co., Ltd.ClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Osteoarthritis
Drug/Device/Intervention
Transcatheter Arterial Micro-Embolization
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Next Biomedical Co., Ltd.
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2023
End date
Dec 01, 2025
Enrollment
50 participants
Primary outcome

Rate of WOMAC Score Reduction,Rate of VAS Score (patient pain intensity) Reduction

Summary

Among knee degenerative osteoarthritis patients aged 50 or older, it will prove the
 therapeutic effect and safety of Nexsphere-F embolization for patients who need additional
 treatment because pain is not controlled even if conventional treatments are taken.

ICD-10 classifications
Other hypertrophic osteoarthropathyOther specified osteochondropathiesPolyarthritis, unspecifiedOther osteochondropathiesOsteochondritis dissecans
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05917028
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05917028 through Pure Global AI's free database. This phase not specified trial is sponsored by Next Biomedical Co., Ltd. and is currently Not yet recruiting. The study focuses on Osteoarthritis. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.